Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus - PubMed (original) (raw)
Affiliations
- PMID: 9128303
Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus
P Sharma et al. Am J Gastroenterol. 1997 Apr.
Abstract
Objective: The importance of esophageal acid control in the management of Barrett's esophagus is controversial. The objective of this study was to assess the impact of esophageal acid control on the symptoms of reflux disease, healing of erosive esophagitis, change in length of Barrett's epithelium, and the appearance of squamous islands.
Methods: Thirteen of 27 patients on 60 mg lansoprazole underwent ambulatory 24 h esophageal pH monitoring while on therapy. Symptoms were recorded, and the length of Barrett's epithelium was measured, photographed, and biopsied every 6 months over an average of 5.7 yr.
Results: Eight of 13 patients had a normal 24 h pH (group I, mean pH < 4, 0.8%), five patients had abnormal results (group II, mean pH < 4, 10.6%). Symptoms improved in all patients, and there was complete healing of erosive esophagitis in all patients. An increase in the number of squamous islands was noted in 62.5% of patients in group I and in 80% of patients in group II. The mean length of Barrett's epithelium at baseline and study completion in group I was 5.6 and 5.0 cm, respectively (mean decrease, 0.6 cm), and for group II was 4.2 and 4.2 cm, respectively (mean decrease, 0 cm). There was no significant difference in the change in length between the two groups (p = 0.494).
Conclusions: Although symptoms improved, erosive esophagitis healed, and squamous islands increased, there was no significant decrease in the length of Barrett's esophagus. Control of esophageal pH alone is not sufficient for the reversal of Barrett's esophagus.
Comment in
- Barrett's esophagus: acid suppression, but no regression.
Bozymski EM, Shaheen NJ. Bozymski EM, et al. Am J Gastroenterol. 1997 Apr;92(4):556-8. Am J Gastroenterol. 1997. PMID: 9128299 No abstract available. - Acid control and regression of Barrett's esophagus: is the glass half full or half empty?
Castell DO, Katz PO. Castell DO, et al. Am J Gastroenterol. 1997 Dec;92(12):2329-30. Am J Gastroenterol. 1997. PMID: 9399786 No abstract available.
Similar articles
- Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus.
Sampliner RE. Sampliner RE. Am J Gastroenterol. 1994 Oct;89(10):1844-8. Am J Gastroenterol. 1994. PMID: 7942680 Clinical Trial. - Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus.
Ouatu-Lascar R, Triadafilopoulos G. Ouatu-Lascar R, et al. Am J Gastroenterol. 1998 May;93(5):711-6. doi: 10.1111/j.1572-0241.1998.211_a.x. Am J Gastroenterol. 1998. PMID: 9625114 - Esophageal mucosal eicosanoids in gastroesophageal reflux disease and Barrett's esophagus.
Triadafilopoulos G, Kaczynska M, Iwane M. Triadafilopoulos G, et al. Am J Gastroenterol. 1996 Jan;91(1):65-74. Am J Gastroenterol. 1996. PMID: 8561146 - Total acid suppression and its effect on Barrett's esophagus.
Castell DO. Castell DO. Am J Manag Care. 2000 Oct;6(16 Suppl):S895-8. Am J Manag Care. 2000. PMID: 11184662 Review. - Reflux disease and Barrett's esophagus.
Haag S, Holtmann G. Haag S, et al. Endoscopy. 2003 Feb;35(2):112-7. doi: 10.1055/s-2003-37013. Endoscopy. 2003. PMID: 12561004 Review.
Cited by
- Barrett's oesophagus: optimal strategies for prevention and treatment.
Fass R, Sampliner RE. Fass R, et al. Drugs. 2003;63(6):555-64. doi: 10.2165/00003495-200363060-00003. Drugs. 2003. PMID: 12656653 Review. - A randomised controlled trial of ablation of Barrett's oesophagus with multipolar electrocoagulation versus argon plasma coagulation in combination with acid suppression: long term results.
Sharma P, Wani S, Weston AP, Bansal A, Hall M, Mathur S, Prasad A, Sampliner RE. Sharma P, et al. Gut. 2006 Sep;55(9):1233-9. doi: 10.1136/gut.2005.086777. Gut. 2006. PMID: 16905695 Free PMC article. Clinical Trial. - Barrett's esophagus: environmental influences in the progression of dysplasia.
Boulton RA, Usselmann B, Mohammed I, Jankowski J. Boulton RA, et al. World J Surg. 2003 Sep;27(9):1014-7. doi: 10.1007/s00268-003-7054-0. Epub 2003 Jul 28. World J Surg. 2003. PMID: 12879287 Review. - Hiatal hernia and acid reflux frequency predict presence and length of Barrett's esophagus.
Avidan B, Sonnenberg A, Schnell TG, Sontag SJ. Avidan B, et al. Dig Dis Sci. 2002 Feb;47(2):256-64. doi: 10.1023/a:1013797417170. Dig Dis Sci. 2002. PMID: 11855539 - Current status of ablative therapies in esophageal disorders.
Sharma P. Sharma P. Curr Gastroenterol Rep. 2001 Jun;3(3):219-24. doi: 10.1007/s11894-001-0025-4. Curr Gastroenterol Rep. 2001. PMID: 11353558 Review.